Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite. This allows cangrelor’s immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion.
Xiao, Yuhua; Li, Yanbing; Wan, Zhenjiang; Chen, Pu; Li, Rong; Sun, Shaoguang; Wu, Chenglong; Huang, Jinkun. Method for preparing (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-((2-(methylthio)ethyl)amino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-3,4-diol WO 2017076266. (Assignee Jiangsu Hengrui Medicine Co., Ltd., Peop. Rep. China; Suncadia Pharmaceuticals Co., Ltd.)
Wang, Yuxuan; David, Jason Allen; Li, Zhi; Wen, Jinfu; Yao, Zhigang. Preparation and application of intermediate of cangrelor. CN 108658989. (Assignee Pharmaster (Ningbo) Technology Co., Ltd., Peop. Rep. China.)
Rajan, Srinivasan Thirumalai; Eswaraiah, Sajja; Reddy, Ghojala Venkat; Reddy, Mallepally Venkat. Improved process for the preparation of N6-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with (dichloromethylene) bisphosphonic acid and its pharmaceutically acceptable salts. WO 2018185715. (Assignee MSN Laboratories Private Limited, R&D Center, India)
